Skip to main content
2024 Annual Meeting Main banner
Final Program


Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Back

Maxwell Sherman, PhD

Co-founder & Chief Technology Officer
Serinus Biosciences

Maxwell is the Chief Science Officer of Serinus Biosciences, a biotechnology company developing novel therapeutics that target treatment resistance mechanisms in tumors. Max holds a PhD in Computer Science from MIT where he worked at the intersection of AI and cancer biology under the mentorship of Dr. Bonnie Berger and Dr. Po-Ru Loh. He also holds a master's degree in mathematical statistics from the University of Cambridge. Max's research focuses on unifying rigorous statistical inference with the predictive power of deep learning to answer fundemental questions about 1) how tumors evolve genomic resistance to existing therapeutics and 2) how novel treatment strategies and drugs can abrogate genomic drivers of drug resistance. He has a particular interest in cell cycle regulators, DNA damage repair agents, and genotoxic chemotherapies.

Disclosure information not submitted.

Presentation(s):